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Effect of Viscum album on acute hepatic damage caused
by carbon tetrachloride in rats
Omar Mohamed ABDEL-SALAM1, Amany Ameen SLEEM1, Nermeen M. SHAFFIE2

Aim: To investigate the effect of Viscum album, a plant used for the treatment of hepatocellular carcinoma that has
immune-modulating properties, on acute hepatic injury in rats.
Materials and methods: Hepatotoxicity was induced by CCl4 orally (0.28 mL/kg). Rats received either Viscum album at
1 of 2 dose levels (0.1 or 0.2 mL/kg) once weekly subcutaneously alone or with silymarin (25 mg/kg, orally), or silymarin
(25 mg/kg) once daily orally for 1 month, starting at the time of administration of CCl4. Liver damage was assessed by
determining liver serum enzyme activities and by hepatic histopathology.
Results: Viscum album administration decreased the increases in serum alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and alkaline phosphatase (ALP), and also prevented the development of hepatic necrosis caused
by CCl4. The effect of Viscum album was dose-dependent. Viscum album administered at 0.1 or 0.2 mL/kg caused
significant reduction in the elevated plasma ALT by 51.2% and 65.6%, AST by 52.6% and 61.1%, and ALP by 27.7% and
57.6%, respectively. In comparison, the elevated serum ALT, AST, and ALP levels decreased to 48.9%, 51.8%, and 30.8%
of the controls, respectively, with 25 mg/kg of silymarin. Viscum album (0.2 mL/kg) administered together with silymarin
resulted in 73.1%, 67.6%, and 65.8% decreases in serum ALT, AST, and ALP levels, respectively. Histopathologic
examination of the livers of rats treated with CCl4 and administered Viscum album at 0.2 mL/kg showed marked
restoration of the normal architecture of the liver tissue with minimal fibrosis.
Conclusion: Results of the present study indicate that the administration of Viscum album in a model of liver injury
induced by CCl4 in rats results in less liver damage.
Key words: Viscum album, hepatic injury, rat, CCl4

Introduction
Currently, the standard therapy for patients with hepatitis C virus infection involves the
combined administration of interferon and ribavirin (1,2). With the use of interferon and ribavirin,
sustained response is obtained in approximately 55% of patients (3,4). Despite the fact that this
combination therapy can eliminate the virus and prevent the progression of the disease, frequent
side effects and relapses preclude the use of this form of therapy in a substantial proportion of
patients (4,5). Thus, it is clear that there is still a need for the identification of compounds that are
capable of modulating chronic inflammation in the liver of such patients because hepatic
inflammation appears to be the key pathological substrate that drives fibrogenesis (6,7).
Apart from interferon-ribavirin therapy, silymarin, a standardized extract of milk thistle
(Silybum marianum), is widely prescribed for chronic liver disease (8). Silymarin possesses
antioxidant properties attributable to its flavonoid components, silibinin, silicristin, and silidianin
(9). In animal models of hepatic injury, the herb has been shown to ameliorate liver injury and to
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exert antifibrotic effects (10-13). Studies in patients
with chronic hepatitis C and alcoholic liver disease
have shown that silymarin increases superoxide
dismutase activity of lymphocytes and erythrocytes
(14), and increases glutathione and decreases lipid
peroxidation in peripheral blood cells (15,16).
Silymarin, however, does not appear to affect viral
load or liver histology in hepatitis B or C (17).
Recently, patients with chronic hepatitis C treated
with Viscum album preparations had a significant
improvement of both AST and ALT (18). Viscum
album preparations consist of aqueous extracts of
Viscum album L., the European mistletoe (family
Loranthaceae). The latter is a semiparasitic plant that
is normally found growing on a variety of trees in
temperate regions worldwide. European mistletoe
preparations are aqueous extracts obtained from the
whole plant. They have cytotoxic and
immunomodulatory properties and are among the
most widely used unconventional cancer therapies in
Germany and Central Europe (19,20). In Germany,
mistletoe extract is listed in certain directories as a
commercially available drug for cancer treatment
(21).
Since there is a need to explore alternative
therapies for chronic liver disease, the present study
aimed to investigate the effect of Viscum album on the
development of experimental liver damage induced
by the administration of the hepatotoxin CCl4 in rats.
The effect of Viscum album was evaluated both on
biochemical markers as well as by histological
techniques and compared with that of silymarin, in
view of the wide use of this plant extract as a
hepatoprotective agent in patients with chronic
hepatitis C.
Materials and methods
Animals
Adult Sprague-Dawley rats of either sex, weighing
120-130 g, were used throughout the experiments and
fed with standard laboratory chow and water ad
libitum. All animal procedures were performed
according to approved protocols and in accordance
with the recommendations for the proper care and use
of laboratory animals.
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Drugs and chemicals
Carbon tetrachloride (BDH Chemicals, England),
Viscum album (viscum fraxini-2, ATOS Pharma Co.,
Cairo), and silymarin (Sedico Pharmaceutical Co.,
Cairo) were used in the experiments. The mistletoe
preparation for the study was an aqueous injectable
solution. It contained 1 mL of viscum fraxini in
dilution stage 2 (15 mg extract of 20 mg mistletoe
herb from ash tree, diluted in Na2HPO4, ascorbic acid,
and water), which is equivalent to 10,000 ng/mL
injection ampoules. Further dilution with distilled
water was done to obtain the necessary doses. The
doses employed were based upon the human dose
after conversion to rat doses according to Paget and
Barnes’ (22) conversion tables.
The carbon tetrachloride model of hepatic
damage
The rats were divided into 6 equal groups of 6 rats
each. Groups 1-5 received CCl4 in olive oil (1:1,
vol/vol) orally at a dose of 2.8 mL/kg. Rats were
administered half the initial dose of CCl4 (0.14
mL/kg) once weekly after the first administration of
CCl4 so as to maintain hepatic damage. Starting on
the first day of CCl4 administration, rats were treated
with saline (CCl4 control, or group 1), Viscum album
(at 1 of 2 dose levels, 0.1 or 0.2 mL/kg) once weekly
subcutaneously (sc) (groups 2 and 3, respectively),
silymarin only (25 mg/kg) orally once daily (group 4),
or Viscum album (0.2 mL/kg, sc) plus silymarin (25
mg/kg, orally) once weekly (group 5) for 30 days. In
addition, another group of rats (n = 6) received saline
but no CCl4 daily for 30 days (group 6). Rats had free
access to food and drinking water during the study.
Biochemical assessment
At the end of the experiments, blood samples were
obtained from the retro-orbital vein plexuses under
ether anesthesia. ALT and AST activities in serum
were measured according to the Reitman-Frankel
colorimetric transaminase procedure (23), whereas
colorimetric determination of ALP activity was done
according to the method of Belfield and Goldberg
(24), using commercially available kits (bioMérieux,
France).
Histopathological studies
After the end of the treatment period, rats were
killed under ether anesthesia, and livers were excised
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and fixed in 10% formalin saline. Sections were
prepared and stained with hematoxylin and eosin
(H&E) for histological investigation.
Statistical analysis
All results are expressed as means ± SE.
Comparison of the values before and after CCl4 was
made by paired Student’s t-test. Multiple group
comparisons were performed by ANOVA followed by
Duncan’s test. P < 0.05 was considered statistically
significant.
Results
Biochemical results
The levels of alanine aminotransferase (ALT),
aspartate aminotransferase (AST), and alkaline
phosphatase (ALP) in plasma were significantly
higher in CCl4-treated rats than in the saline control
group, indicating the severity of hepatic injury and
cholestasis caused by CCl4. Thus, compared with the
saline control group, ALT, AST, and ALP were raised
by 222%, 173.4%, and 186.5%, respectively (Table).
Viscum album administered at 0.1 mL/kg significantly
reduced the elevated plasma ALT by 51.2%, AST by
52.6%, and ALP by 27.7%. Viscum album at the higher
dose of 0.2 mL/kg significantly decreased the raised
plasma ALT by 65.6%, AST by 61.1%, and ALP by
57.6%. In comparison, the elevated serum ALT, AST,
and ALP levels were decreased to 48.9%, 51.8%, and
30.8% of the controls, respectively, with 25 mg/kg of
Table.

silymarin. Viscum album (0.2 mL/kg) combined with
silymarin resulted in 73.1%, 67.6%, and 65.8%
decreases in serum ALT, AST, and ALP levels,
respectively (Table).
Histopathological results
The livers of saline control rats revealed the
characteristic hepatic architecture (Figure 1). The liver
of rats subjected to CCl4 showed loss of liver tissue
architecture, severe dilatation and congestion of blood
vessels (either central veins or portal tract vessels),
marked lymphocytic infiltration, and fibrosis
extending between the portal areas (Figure 2).
Sections of liver tissue from rats treated with Viscum
album at 0.1 mL/kg showed slight distortion of the
normal architecture of liver tissue with marked
dilatation and congestion of the portal veins in portal
areas (Figure 3). Sections of liver tissue from rats
treated with Viscum album at 0.2 mL/kg showed
preserved liver architecture with marked dilatation of
blood sinusoids, denoting edema with congestion and
dilatation of blood vessels (Figure 4).
Discussion
In the present study, acute hepatic injury was
induced by injection of CCl4 in rats, leading to high
levels of serum aminotransferases and considerable
perivenular necrosis. Hepatic injury was reduced by
once weekly administration of Viscum album with a
reduction in plasma levels of hepatocellular enzymes

Effect of Viscum album, silymarin, or Viscum album plus silymarin on serum alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and alkaline phosphatase (ALP) in CCl4-treated rats.

Treatment

ALT (U/L)

AST (U/L)

ALP (IU/L)

Saline control

71.0 ± 3.1

80.4 ± 2.5

50.9 ± 1.9

CCl4 control

228.6 ± 10.0

219.8 ± 3.7

146.1 ± 6.0

CCl4 + viscum album 0.1 mL/kg

111.5 ± 3.5*

104.1 ± 3.4*

105.7 ± 4.1*

CCl4 + viscum album 0.2 mL/kg

78.7 ± 3.1*+

85.5 ± 5.2*+

62.0 ± 5.2*+

CCl4 + silymarin 25 mg/kg

116.8 ± 6.7

*

106.0 ± 8.1

*

101.0 ± 7.1*

CCl4 + silymarin + viscum album 0.2 mL/kg

61.6 ± 3.4*+

71.2 ± 2.5*+

50.0 ± 2.6*+

Results were means ± S.E. Data were analyzed by one-way ANOVA and the means of different groups were compared with Duncan’s
multiple range test. *: P < 0.05 compared with the CCl4 control group. +: P < 0.05 compared with groups treated with Viscum album
0.2 mL/kg or silymarin alone.
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Figure 1-4. (1) A photomicrograph of a section of liver tissue of a control rat showing the central vein and the hepatocytes arranged in
cords radiating from the central vein (C) in an anastomosing manner to form a spongework or labyrinth (H&E, ×200).
(2) A photomicrograph of a section of liver tissue of a rat treated with carbon tetrachloride showing distortion of the normal
architecture of the liver tissue. Bundles of collagen fibers with fibrocytes (arrow) are surrounding the portal tract components,
especially the portal vein (P). These components show dilatation with congestion in the portal vein. The blood sinusoids show
dilatation (arrow head), and also the bile duct (B) (H&E, ×200).
(3) A photomicrograph of a section of liver tissue of a rat treated with carbon tetrachloride and 0.1 mL/kg of Viscum album
showing most of the hepatocytes being normal in appearance and arrangement, with no dilatation of the blood sinusoids.
Collagenous fibers with fibrocytes are observed in between the hepatocytes (arrow). Marked dilatation and congestion of
blood vessels is seen in the left part of the figure (H&E, ×200).
(4) A photomicrograph of a section of liver tissue of a rat treated with carbon tetrachloride and 0.2 mL/kg of Viscum album
showing a nearly normal appearance of liver tissue, except for the dilated and congested blood sinusoids (arrow). Both the
central vein (C) and the hepatocytes are of normal size and shape (H&E, ×200).

ALT and AST as well as the cell membrane enzyme
ALP and with marked improvement in liver
morphology. These results pointed to a hepatic
protective effect of Viscum album. The study also
indicated the usefulness of combining both Viscum
album and silymarin.
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Little information is available in the literature on
the effect of Viscum album on hepatic injury. The
plant, however, has been widely investigated for its
anticancer properties (19,20). Two recent studies done
in patients with chronic hepatitis C, treated with a
mistletoe preparation as monotherapy for 1 year,
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reported a significant improvement in elevated
transaminases (25). The mechanism(s) by which
Viscum album modulates hepatic inflammation
remains, however, unclear. Viscum album extracts
contain mistletoe lectins, cytotoxic glycoproteins also
known as viscumin or agglutinin, which are members
of the family of type 2 ribosome-inactivating proteins,
and viscotoxin, which is a 46-amino acid peptide that
damages cell membranes (26). Other constituents
include polysaccharides (galacturonan and
arabinogalactan) and alkaloids. Viscum album
extracts have both immunomodulatory (induces
TNF-α and IL-12) and apoptosis-inducing properties,
which are likely to be dose-dependant (27). The
perioperative administration of Viscum album
attenuated the immuno-suppressive effects of surgery,
increasing the number of NK cells, the T and B cells,
complement, and IgA, IgG, and IgM values (28).
Studies also suggested that European mistletoe
possesses insulin-secreting (29), antihyperglycemic,
antioxidant activity (30), and cholinomimetic
activities (31) for Viscum album L.
Findings in the present study suggest that the use
of silymarin with Viscum album can have an additive
beneficial effect in lessening liver inflammation and
necrosis caused by CCl4. The release of
aminotransferases into the plasma was markedly
reduced, indicating a reduction in the severity of liver

damage by the combination. Aminotransferases are
sensitive indicators of liver-cell injury and are released
into the blood in increasing amounts whenever the
liver cell membrane is damaged (32). Silymarin, a
standardized plant extract, has been used for many
years as a hepatoprotective agent (8,9). In patients
with liver disease, silymarin increased superoxide
dismutase activity of lymphocytes and erythrocytes
(14), and increased glutathione and decreased lipid
peroxidation in peripheral blood cells (15,16). In in
vitro models of hepatotoxicity, silymarin decreased
lactate dehydrogenase leakage, increased oxygen
consumption, reduced the formation of lipid
peroxides (malondialdehyde), and reduced the
increased Ca++ in hepatocytes (33). Silymarin also
possesses important antiinflammatory properties,
inhibiting the migration of neutrophils into the
inflamed site (34), which are likely to be of relevance
to its hepatoprotective effects.
Mistletoe preparations are among the most widely
used unconventional cancer therapies in many
countries (19,20). The results of the present study
suggest that mistletoe preparations may be a useful
therapeutic intervention for patients with chronic
liver disease. Clearly, further studies are required to
elucidate the mechanism(s) by which mistletoe
preparations exert their hepatoprotective effects seen
in the present study.
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